- Stocks
- Pharma & Healthcare
- Mankind Pharma
Mankind Pharma share price
NSE: MANKINDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Mankind Pharma at a glance
Mankind Pharma (NSE: MANKIND) closed at ₹2,236.60 on 22 Oct 2026, down 1.69% on the day. With a market capitalisation of ₹93,981 Cr, it ranks 114th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 48.4× trailing earnings, against a return on equity of 11.7% in FY26. Over the past year the share price has fallen 8.1%. Its 52-week range is ₹1,909.70 (23 Mar 2026) to ₹2,642.00 (29 Jul 2026); the last close is 15.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4,031 Cr (+12.9% year on year) and net profit ₹570 Cr (+29.2%), on a consolidated basis. Promoters held 72.63% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹93,981 CrRank 114 on NSE
- P/E (trailing)
- 48.4×
- Price to book
- 5.08×FY26
- EPS (TTM)
- ₹49.49to Q1 FY27
- ROE
- 11.7%FY26
- ROCE
- 14.3%FY26
- Debt to equity
- 0.38FY26
- Net profit margin
- 13.5%FY26
- Book value / share
- ₹394.87FY26
- Dividend payout
- 2.2%FY26
- 52-week high
- ₹2,642.0029 Jul 2026
- 52-week low
- ₹1,909.7023 Mar 2026
- 1-year return
- −8.1%
- RSI (14-day)
- 35
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.69% | −4.2% | −8.0% | −11.7% | −8.1% |
Mankind Pharma quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,077 Cr | ₹3,230 Cr | ₹3,079 Cr | ₹3,570 Cr | ₹3,697 Cr | ₹3,567 Cr | ₹3,443 Cr | ₹4,031 Cr |
| Revenue YoY | +13.6% | +23.9% | +26.1% | +23.4% | +20.2% | +10.4% | +11.8% | +12.9% |
| Net profit | ₹656 Cr | ₹381 Cr | ₹422 Cr | ₹441 Cr | ₹518 Cr | ₹411 Cr | ₹556 Cr | ₹570 Cr |
| Net profit YoY | +29.3% | −16.3% | −10.9% | −18.1% | −21.1% | +7.8% | +31.8% | +29.2% |
| Net margin | 21.3% | 11.8% | 13.7% | 12.4% | 14.0% | 11.5% | 16.2% | 14.1% |
| EPS | ₹16.31 | ₹9.45 | ₹10.20 | ₹10.62 | ₹12.39 | ₹9.90 | ₹13.44 | ₹13.76 |
Mankind Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹6,214 Cr | ₹7,782 Cr | ₹8,749 Cr | ₹10,335 Cr | ₹12,207 Cr | — |
| Operating profit | ₹1,680 Cr | ₹1,960 Cr | ₹1,659 Cr | ₹2,384 Cr | ₹2,504 Cr | — |
| Net profit | ₹1,281 Cr | ₹1,439 Cr | ₹1,297 Cr | ₹1,927 Cr | ₹1,999 Cr | — |
| EPS (₹) | ₹32.00 | ₹36.00 | ₹32.00 | ₹48.00 | ₹49.00 | — |
| Cash from operations | ₹1,137 Cr | ₹920 Cr | ₹1,813 Cr | ₹2,152 Cr | ₹2,413 Cr | — |
| Total debt | ₹62 Cr | ₹52 Cr | ₹23 Cr | ₹25 Cr | ₹5,526 Cr | ₹2,821 Cr |
| Shareholders' equity | ₹4,722 Cr | ₹6,155 Cr | ₹7,435 Cr | ₹9,363 Cr | ₹14,332 Cr | ₹16,300 Cr |
Mankind Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.70% | 72.68% | 72.67% | 72.66% | 72.66% | 72.63% |
| Foreign institutions | 12.92% | 13.07% | 12.84% | 11.34% | 10.24% | 9.45% |
| Domestic institutions | 11.48% | 11.50% | 11.92% | 13.25% | 14.46% | 15.39% |
| Non-institutions | 2.90% | 2.75% | 2.57% | 2.75% | 2.64% | 2.53% |
Mankind Pharma vs peers
The listed Pharma & Healthcare companies nearest to Mankind Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,569.50 | −0.41% | −2.4% | ₹1,09,341 Cr | 56 | 20.5% |
| LAURUSLABSLaurus Labs | ₹2,010.10 | +0.02% | +129.8% | ₹1,08,185 Cr | 121.7 | 8.0% |
| CIPLACipla | ₹1,312.60 | +0.08% | −15.2% | ₹1,07,516 Cr | 27.3 | 11.3% |
| DRREDDYDr. Reddy's Laboratories | ₹1,236.20 | −0.26% | +0.0% | ₹1,03,416 Cr | 25 | 11.1% |
| MANKINDMankind Pharma | ₹2,236.60 | −1.69% | −8.1% | ₹93,981 Cr | 48.4 | 11.7% |
| AUROPHARMAAurobindo Pharma | ₹1,571.30 | −0.01% | +40.0% | ₹92,688 Cr | 26 | 9.2% |
| LUPINLupin | ₹1,929.60 | −0.64% | −0.3% | ₹87,880 Cr | 16.6 | 23.8% |
Ask anything about Mankind Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against MANKIND's own history. Try: “Why has MANKIND moved over the last three months?” · “Backtest a 50-day moving-average crossover on MANKIND over five years” · “Compare MANKIND with APOLLOHOSP on margins and valuation”
Frequently asked questions about Mankind Pharma
What is the share price of Mankind Pharma today?
Mankind Pharma (NSE: MANKIND) last closed at ₹2,236.60 on 22 Oct 2026. Its 52-week high is ₹2,642.00 and its 52-week low is ₹1,909.70.
What is the market cap of Mankind Pharma?
Mankind Pharma's market capitalisation is ₹93,981 Cr (₹93,981 Cr) at the 22 Oct 2026 close, ranking 114th among the NSE companies Pivot tracks.
What is the P/E ratio of Mankind Pharma?
Mankind Pharma trades at a trailing P/E of 48.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 27.3.
What is the ROE and ROCE of Mankind Pharma?
Return on equity was 11.7% in FY26 and return on capital employed was 14.3% in FY26 (consolidated figures).
Is Mankind Pharma a debt-free company?
No. Mankind Pharma's debt-to-equity ratio was 0.38 in FY26, with total debt of ₹2,821 Cr.
What were Mankind Pharma's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Mankind Pharma reported revenue of ₹4,031 Cr, +12.9% year on year, and net profit of ₹570 Cr, +29.2% year on year.
How has Mankind Pharma stock performed over the last year?
Mankind Pharma's share price has fallen 8.1% over the past year, −11.7% over three months and −8.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Mankind Pharma?
As of 30 Jun 2026: promoters 72.63%, foreign institutions 9.45%, domestic institutions 15.39%, non-institutions 2.53%.
Who are Mankind Pharma's competitors?
The listed Pharma & Healthcare companies closest to Mankind Pharma by market cap are Apollo Hospitals Enterprise, Laurus Labs, Cipla, Dr. Reddy's Laboratories, Aurobindo Pharma and Lupin.
Is Mankind Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Mankind Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MANKIND against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text